Research and Developments

Page 2 of 1812345...10...Last »

December 6, 2016

Photobiomodulation—A New Treatment For Dry AMD?

Posted in: Latest News, Research and Developments

A new non-invasive technology from LumiThera Inc. may help improve vision in  people with dry age-related macular degeneration. Photobiomodulation involves exposure of the retina to light from diodes emitting red, yellow, and infrared wavelengths. Researchers in Switzerland and Toronto recently found that treating eyes three times a week for three weeks improved best corrected visual
read more »

November 22, 2016

Eye Drops for Wet AMD Showing Positive Results

Posted in: Latest News, Research and Developments

Eye drops continue to show promise as future treatments for wet AMD and other eye diseases involving blood vessel growth and hemorrhaging in the retina. In a presentation at the 2015 Ophthalmology Innovation Summit at the American Academy of Ophthalmology. Paul G. Chaney (President and CEO of Panoptica) reported preliminary results from the PAN-90806 clinical
read more »

October 13, 2016

FDA Grants Priority Review for Myopic CNV Treatment

Posted in: Latest News, Research and Developments

Genentech, makers of Lucentis® (ranibizumab injection) for wet AMD, has been approved for Priority Review by the FDA to study Lucentis for the treatment of myopic choroidal neovascularization (mCNV). Also known as degenerative myopia, mCNV is a complication of severe near-sightedness that can lead to uncorrectable visual impairment. The FDA’s approval is based on results from the Phase
read more »

October 13, 2016

RADIANCE Study for Treatment of Myopic Degeneration

Posted in: Research and Developments

RADIANCE is a Phase III, 12-month, randomized, double-masked, multicenter, active-controlled study comparing the efficacy and safety of Lucentis (0.5 mg) versus verteporfin photodynamic therapy (vPDT) in 277 patients with visual impairment due to myopic choroidal neovascularization (mCNV). Patients were randomized into three treatment groups: 106 patients in group I received treatment with Lucentis on study
read more »

September 10, 2016

Combined Therapies May Help Restore Vision Loss From Glaucoma

Posted in: Latest News, Research and Developments

Past studies have shown that high-contrast visual stimulation can help damaged retinal neurons regrow optic nerve fibers. By combining that knowledge with new research showing that increased activity of a protein called mTOR promotes optic nerve regeneration, scientists are hoping for a way to restore sight lost to glaucoma and other optic neuropathies. So far,
read more »

August 10, 2016

Is Blindness The “Worst Ailment”?

Posted in: Daily Living, Latest News, Low Vision Rehabilitation, Research and Developments

by Dan Roberts A recent online nationwide poll (1) has joined similar past studies in revealing that people consider vision loss to be the “worst ailment that could happen to them relative to losing memory, speech, hearing, or a limb.” The researchers’ intent was to “underscore the importance of focusing on preservation of eye health and the
read more »

July 27, 2016

Finally, A Promising Breakthrough For Dry AMD

Posted in: Latest News, Research and Developments

Genentech, Inc., a leading pharmaceutical developer, is currently conducting two phase III trials studying the drug lampalizumab as a potential treatment for advanced dry macular degeneration, also known as geographic atrophy (GA). Patients who have been diagnosed with GA are encouraged to participate in the trials, which are being conducted at hundreds of locations in
read more »

July 19, 2016

Anti-depressant Drugs May Someday Help Prevent Macular Degeneration

Posted in: Latest News, Research and Developments

Tests in a mouse model of macular degeneration have shown that anti-depressant drugs already on the market prevent damage to the light cells in the retina. In a study published in Proceedings of the National Academy of Sciences, a University of Wisconsin—Madison research team pinpoints how immune abnormalities beneath the retina result in macular degeneration.
read more »

June 9, 2016

For Some, Switching ANTI-VEGF Treatments Midstream Could Be Harmful

Posted in: Latest News, Research and Developments, Therapies, Treatments, and Procedures

Switching from Lucentis to Eylea could result in worsening of the retinal condition of some people with wet (exudative) AMD. Since the advent of anti-VEGF drug treatments for wet AMD, research has verified that blood vessel growth and leakage (neovascularization) usually diminishes in patients who are switched from either Lucentis or Avastin to Eylea. A small
read more »

May 28, 2016

Summary of Research and Development — 2016

Posted in: Research and Developments

ILVSG Presentation June 2016 Dan Roberts I. INTRODUCTION This is my 11th annual summary of leading research and developments that have occurred during the past 12 months in the field of blindness and low vision. I’ll take the liberty in several cases of quoting the sources, but for the sake of conversational flow, I’ll break
read more »

Page 2 of 1812345...10...Last »

Custom Wordpress design and web development by Jeff Roberts Web Design

WP-Backgrounds by InoPlugs Web Design and Juwelier Schönmann